Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseases

HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) --  Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform.

The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia’s core platform technology. Corresponding patents have also been granted in Europe and Japan, with additional applications pending in other major global jurisdictions.

U.S. Patent No. 12,502,408 relates to Minovia’s proprietary mitochondrial augmentation technology for the treatment of primary mitochondrial diseases. The claims cover Minovia’s lead program, MNV-201, which consists of autologous hematopoietic stem cells enriched with placental-derived mitochondria. MNV-201 is currently being evaluated in clinical trials for Pearson Syndrome and other severe genetic mitochondrial disorders.

U.S. Patent No. 12,329,781 relates to Minovia’s proprietary mitochondrial augmentation technology for the treatment of renal diseases, including renal tubulopathy, kidney insufficiency, and chronic kidney disease (CKD), broadening the potential therapeutic applications of the MAT platform beyond primary mitochondrial disorders.

“These new patent grants strengthen and protect Minovia’s intellectual property and underscore the versatility of our proprietary mitochondrial augmentation platform across multiple serious disease areas,” said Minovia Co-founder and CEO, Natalie Yivgi-Ohana, Ph.D. “Securing protection for both our lead mitochondrial disease program and our expanding renal disease applications supports our long-term strategy to develop transformative therapies to effectively treat patients with high unmet medical needs.”